Xeris Pharmaceuticals | XERS

Stock Price
7.82
Daily Change
-0.04 -0.45%
Monthly
42.35%
Yearly
211.35%
Q3 Forecast
7.78


Financials
Assets USD 334.69M
Cash and Equivalent USD 59.28M
Cost of Sales USD 11.9M
Current Assets USD 185.58M
Current Liabilities USD 95.17M
Debt USD 257.22M
EBIT USD 5.43M
EBITDA USD 8.59M
Employees 377
EPS Earnings Per Share USD -0.01
Equity Capital and Reserves USD -19.3M
Gross Profit on Sales USD 59.64M
Interest Expense on Debt USD 7.36M
Interest Income USD 948K
Loan Capital USD 218.63M
Market Capitalization USD 1.1B
Net Income USD -1.93M
Operating Expenses USD 67.06M
Operating Profit USD 4.48M
Ordinary Share Capital USD 161.22M
Pre-Tax Profit USD -1.93M
Sales Revenues USD 71.54M
Selling and Administration Expenses USD 44.39M
Stock USD 67.28M
Trade Creditors USD 9.46M
Trade Debtors USD 53.05M
Peers Price Chg Day Year Date
Celltrion 170,000.00 1,000.00 0.59% -11.50% Sep/08
Cspc Pharmaceutical 11.48 0.29 2.59% 146.35% Sep/08
Sino Biopharmaceutical 9.01 0.10 1.12% 186.94% Sep/08
Zhangzhou Pientzehuang Pharmaceutical 205.80 1.93 0.95% 1.59% Sep/08
Kangmei Pharma 2.04 0.01 0.49% 15.91% Sep/08
Adcock Ingram Holdings 7,225.00 38.00 0.53% 11.24% Sep/08
Divis Laboratories Ltd 6,031.50 22.50 0.37% 16.58% Sep/08
Knight Therapeutics 6.42 -0.02 -0.31% 14.03% Sep/08
Eli Lilly 738.75 11.54 1.59% -18.66% Sep/08
Dianthus Therapeutics 25.24 -1.26 -4.75% -5.18% Sep/08
Malin Corporation 7.90 -0.10 -1.25% 25.40% Sep/08
Medical Developments International 0.57 -0.01 -0.87% 35.71% Sep/08
Neuren Pharmaceuticals 20.80 0.32 1.56% 51.27% Sep/08
Organigram Holdings 2.24 -0.04 -1.75% -9.68% Sep/08
Pacira 26.23 -0.23 -0.85% 98.22% Sep/08
Pharma Mar 87.95 -0.45 -0.51% 112.13% Sep/08
Perrigo 22.65 -0.64 -2.75% -20.79% Sep/05
Qiagen NV 40.52 0.13 0.32% -1.06% Sep/08
Laboratorios Farma 59.90 0.25 0.42% -27.17% Sep/08
Sartorius 195.25 2.05 1.06% -22.61% Sep/08
Supernus Pharmaceuticals 46.24 0.24 0.52% 36.64% Sep/08
Tilray 1.52 -0.12 -7.32% -34.48% Sep/08


Xeris Pharmaceuticals Inc traded at $7.82 this Monday September 8th, decreasing $0.04 or 0.45 percent since the previous trading session. Looking back, over the last four weeks, Xeris Pharmaceuticals lost 42.35 percent. Over the last 12 months, its price rose by 211.35 percent. Looking ahead, we forecast Xeris Pharmaceuticals Inc to be priced at 7.78 by the end of this quarter and at 7.59 in one year, according to Trading Economics global macro models projections and analysts expectations.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.